InspireMD, Inc. (NSPR)
NASDAQ: NSPR · Real-Time Price · USD
2.430
-0.010 (-0.41%)
Jul 30, 2025, 4:00 PM - Market closed

Company Description

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific.

The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions.

It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions.

The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida.

InspireMD, Inc.
InspireMD logo
CountryUnited States
Founded2005
IndustryMedical Devices
SectorHealthcare
Employees86
CEOMarvin Slosman

Contact Details

Address:
6303 Waterford District Drive, Suite 215
Miami, Florida 33126
United States
Phone888 776 6804
Websiteinspiremd.com

Stock Details

Ticker SymbolNSPR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001433607
CUSIP Number45779A853
ISIN NumberUS45779A8466
Employer ID26-2123838
SIC Code3841

Key Executives

NamePosition
Marvin L. SlosmanPresident, Chief Executive Officer and Director
Craig ShoreChief Financial Officer, Chief Administrative Officer, Secretary and Treasurer
Shane Thomas GleasonChief Commercial Officer
Andrea TommasoliChief Operating Officer
Amir KohenExecutive Vice President of Finance and Regional Manager
Pete J. LigottiExecutive Vice President and GM of North America
Dr. Sol J. Barer Ph.D.Special Advisor to the Board

Latest SEC Filings

DateTypeTitle
Jul 9, 20258-KCurrent Report
Jun 24, 20258-KCurrent Report
Jun 13, 20258-KCurrent Report
Jun 3, 20258-KCurrent Report
Jun 3, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 12, 2025SCHEDULE 13G/AFiling
May 9, 20258-KCurrent Report
May 8, 202510-QQuarterly Report